| __timestamp | MannKind Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 47795223 |
| Thursday, January 1, 2015 | 29674000 | 50426000 |
| Friday, January 1, 2016 | 14917000 | 70853000 |
| Sunday, January 1, 2017 | 14118000 | 78168000 |
| Monday, January 1, 2018 | 8737000 | 123757000 |
| Tuesday, January 1, 2019 | 6900000 | 140963000 |
| Wednesday, January 1, 2020 | 6248000 | 131773000 |
| Friday, January 1, 2021 | 12312000 | 210328000 |
| Saturday, January 1, 2022 | 19721000 | 235780000 |
| Sunday, January 1, 2023 | 31283000 | 244990000 |
Unleashing insights
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, MannKind Corporation and Travere Therapeutics, Inc. have been at the forefront of this race. From 2014 to 2023, Travere Therapeutics consistently outpaced MannKind in research and development (R&D) spending. In 2023, Travere's R&D expenses were nearly eight times higher than MannKind's, highlighting their commitment to innovation. While MannKind's investment peaked in 2014, Travere's spending has shown a steady upward trend, culminating in a 413% increase over the decade. This strategic focus on R&D positions Travere as a leader in the biotech sector, potentially driving groundbreaking advancements. As the industry evolves, these investments could be pivotal in shaping the future of healthcare.
R&D Spending Showdown: Novartis AG vs Travere Therapeutics, Inc.
Amgen Inc. or Travere Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Zoetis Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Jazz Pharmaceuticals plc vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How Amneal Pharmaceuticals, Inc. and Travere Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs MannKind Corporation
R&D Insights: How PTC Therapeutics, Inc. and MannKind Corporation Allocate Funds
Perrigo Company plc vs Travere Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Veracyte, Inc. vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Vericel Corporation and Travere Therapeutics, Inc.
Research and Development Investment: Catalyst Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.